Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial

20171 citationsJournal Article

Authors

Good health and well-being

Published in: Clinical Lymphoma Myeloma & Leukemia

Volume 17, pp. S316-S316

Field-Weighted Citation Impact: 0.00